These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30885060)

  • 1. Antithrombotic Therapy After Revascularization in Patients With Peripheral Arterial Disease: What Is Here, What Is Next.
    Amer MR; Chaturvedula ST; Joshi S; Ingrassia J
    Vasc Endovascular Surg; 2019 May; 53(4):325-336. PubMed ID: 30885060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic treatment in peripheral artery disease.
    Olinic DM; Tataru DA; Homorodean C; Spinu M; Olinic M
    Vasa; 2018 Feb; 47(2):99-108. PubMed ID: 29160765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic therapy in peripheral artery disease.
    Foley TR; Waldo SW; Armstrong EJ
    Vasc Med; 2016 Apr; 21(2):156-69. PubMed ID: 26823456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic Therapy for Peripheral Revascularisation.
    De Carlo M; Angelillis M; Liga R
    Curr Vasc Pharmacol; 2020; 18(3):223-236. PubMed ID: 30727899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases.
    Savarese G; Reiner MF; Uijl A; D'Amario D; Agewall S; Atar D; Baumgartner I; Borghi C; De Carlo M; Drexel H; Kaski JC; Kjeldsen KP; Kucher N; Lund LH; Niessner A; Semb AG; Schmidt TA; Sulzgruber P; Tamargo J; Vitale C; Wassmann S; Aboyans V; Lewis BS
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):86-93. PubMed ID: 31392312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Intravenous Thrombolysis and Antithrombotic Agents in Stroke: An Update.
    Derex L; Paris C; Nighoghossian N
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29331961
    [No Abstract]   [Full Text] [Related]  

  • 7. Antithrombotics in stable peripheral artery disease.
    Kaplovitch E; Rannelli L; Anand SS
    Vasc Med; 2019 Apr; 24(2):132-140. PubMed ID: 30799766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban in peripheral artery disease: The new kid on the block?
    Hussain MA; Verma S; Al-Omran M
    J Vasc Surg; 2018 Mar; 67(3):985-986. PubMed ID: 29477208
    [No Abstract]   [Full Text] [Related]  

  • 9. Antithrombotic Therapy in Lower Extremity Artery Disease.
    Vrsalovic M; Aboyans V
    Curr Vasc Pharmacol; 2020; 18(3):215-222. PubMed ID: 30727898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic therapy use after percutaneous coronary intervention and stent implantation in patients taking chronic oral anticoagulation.
    Ruiz-Nodar JM; Marín F; Lip GY
    JACC Cardiovasc Interv; 2008 Jun; 1(3):329; author reply 330-1. PubMed ID: 19463322
    [No Abstract]   [Full Text] [Related]  

  • 11. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
    Tangelder MJ; Nwachuku CE; Jaff M; Baumgartner I; Duggal A; Adams G; Ansel G; Grosso M; Mercuri M; Shi M; Minar E; Moll FL
    J Endovasc Ther; 2015 Apr; 22(2):261-8. PubMed ID: 25809373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of observational research studying the long-term use of antithrombotic medicines following intracerebral hemorrhage.
    Flynn RW; MacDonald TM; Murray GD; Doney AS
    Cardiovasc Ther; 2010 Jun; 28(3):177-84. PubMed ID: 20337638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.
    Angiolillo DJ; Goodman SG; Bhatt DL; Eikelboom JW; Price MJ; Moliterno DJ; Cannon CP; Tanguay JF; Granger CB; Mauri L; Holmes DR; Gibson CM; Faxon DP
    Circulation; 2018 Jul; 138(5):527-536. PubMed ID: 30571525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic therapy in 2017: Advances in atherosclerosis, atrial fibrillation, and valvular disease.
    Bhatt DL
    Nat Rev Cardiol; 2018 Feb; 15(2):71-72. PubMed ID: 29297509
    [No Abstract]   [Full Text] [Related]  

  • 15. Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease.
    Hess CN; Bonaca MP
    Circ Cardiovasc Interv; 2020 Oct; 13(10):e009584. PubMed ID: 33023325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease.
    Cairns JA; McMurtry MS
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S60-70. PubMed ID: 23790600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic Therapy After Transcatheter Aortic Valve Replacement.
    Guedeney P; Mehran R; Collet JP; Claessen BE; Ten Berg J; Dangas GD
    Circ Cardiovasc Interv; 2019 Jan; 12(1):e007411. PubMed ID: 30630354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Return of Oral Anticoagulation in Chronic Stable Coronary Disease.
    Verheugt FWA
    Circulation; 2018 Apr; 137(16):1655-1657. PubMed ID: 29661947
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial.
    Qamar A; Morrow DA; Creager MA; Scirica BM; Olin JW; Beckman JA; Murphy SA; Bonaca MP
    Vasc Med; 2020 Apr; 25(2):124-132. PubMed ID: 32000630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.